Src signaling in cancer invasion
- PMID: 20049846
- DOI: 10.1002/jcp.22011
Src signaling in cancer invasion
Abstract
Src is a non-receptor cytoplasmic tyrosine kinase which becomes activated following the stimulation of plasma membrane receptors including receptor tyrosine kinases and integrins, and is an indispensable player of multiple physiological homeostatic pathways. Once activated, Src is the starting point for several biochemical cascades that thereby propagate signals generated extracellularly along intracellular interconnected transduction pathways. Src transmits signals promoting cell survival and mitogenesis and, in addition, exerts a profound effect on the reorganization of the cytoskeleton and the adhesion systems that underpin cell migration and invasion. Because increased activity of Src is a frequent occurrence in many types of human cancer, and because there is evidence of a prominent role of Src in invasion and in other tumor progression-related events such as epithelial-mesenchymal transition (EMT) and development of metastasis, inhibitors targeting Src are being viewed as promising drugs for cancer therapy.
J. Cell. Physiol. 223: 14-26, 2010. (c) 2009 Wiley-Liss, Inc.
Similar articles
-
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.Cancer Res. 2007 Feb 15;67(4):1580-8. doi: 10.1158/0008-5472.CAN-06-2027. Cancer Res. 2007. PMID: 17308097
-
Signal transduction by focal adhesion kinase in cancer.Cancer Metastasis Rev. 2009 Jun;28(1-2):35-49. doi: 10.1007/s10555-008-9165-4. Cancer Metastasis Rev. 2009. PMID: 19169797 Review.
-
Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.J Biomed Sci. 2005;12(4):571-85. doi: 10.1007/s11373-005-7212-5. Epub 2005 Nov 10. J Biomed Sci. 2005. PMID: 16132110
-
[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].Klin Onkol. 2010;23(4):203-9. Klin Onkol. 2010. PMID: 20806817 Review. Czech.
-
Integrin-regulated FAK-Src signaling in normal and cancer cells.Curr Opin Cell Biol. 2006 Oct;18(5):516-23. doi: 10.1016/j.ceb.2006.08.011. Epub 2006 Aug 17. Curr Opin Cell Biol. 2006. PMID: 16919435 Review.
Cited by
-
Anti-Breast Cancer Effect of 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione in vivo and in vitro Through MAPK Signaling Pathway.Drug Des Devel Ther. 2020 Jul 7;14:2667-2684. doi: 10.2147/DDDT.S237699. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32764871 Free PMC article.
-
Dasatinib in recurrent glioblastoma: failure as a teacher.Neuro Oncol. 2015 Jul;17(7):910-1. doi: 10.1093/neuonc/nov086. Epub 2015 May 10. Neuro Oncol. 2015. PMID: 25964312 Free PMC article. No abstract available.
-
SRC: a century of science brought to the clinic.Neoplasia. 2010 Aug;12(8):599-607. doi: 10.1593/neo.10328. Neoplasia. 2010. PMID: 20689754 Free PMC article. Review.
-
Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.Expert Rev Neurother. 2019 Jul;19(7):663-677. doi: 10.1080/14737175.2019.1621169. Epub 2019 May 27. Expert Rev Neurother. 2019. PMID: 31106606 Free PMC article. Review.
-
Tocotrienols fight cancer by targeting multiple cell signaling pathways.Genes Nutr. 2012 Jan;7(1):43-52. doi: 10.1007/s12263-011-0220-3. Epub 2011 Apr 9. Genes Nutr. 2012. PMID: 21484157 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous